Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

613 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Direct conversion of osteosarcoma to adipocytes by targeting TNIK.
Hirozane T, Masuda M, Sugano T, Sekita T, Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, Asano N, Nakamura M, Matsumoto M, Nakayama R, Kondo T, Kawai A, Kobayashi E, Yamada T. Hirozane T, et al. Among authors: sawa m. JCI Insight. 2021 Feb 8;6(3):e137245. doi: 10.1172/jci.insight.137245. JCI Insight. 2021. PMID: 33400690 Free PMC article.
Targeting the Wnt signaling pathway in colorectal cancer.
Sawa M, Masuda M, Yamada T. Sawa M, et al. Expert Opin Ther Targets. 2016;20(4):419-29. doi: 10.1517/14728222.2016.1098619. Epub 2015 Oct 6. Expert Opin Ther Targets. 2016. PMID: 26439805 Review.
TNIK inhibition abrogates colorectal cancer stemness.
Masuda M, Uno Y, Ohbayashi N, Ohata H, Mimata A, Kukimoto-Niino M, Moriyama H, Kashimoto S, Inoue T, Goto N, Okamoto K, Shirouzu M, Sawa M, Yamada T. Masuda M, et al. Among authors: sawa m. Nat Commun. 2016 Aug 26;7:12586. doi: 10.1038/ncomms12586. Nat Commun. 2016. PMID: 27562646 Free PMC article.
Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors.
Irie T, Asami T, Sawa A, Uno Y, Hanada M, Taniyama C, Funakoshi Y, Masai H, Sawa M. Irie T, et al. Among authors: sawa a, sawa m. Eur J Med Chem. 2017 Apr 21;130:406-418. doi: 10.1016/j.ejmech.2017.02.030. Epub 2017 Feb 17. Eur J Med Chem. 2017. PMID: 28279847
Feasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma.
Sekita T, Yamada T, Kobayashi E, Yoshida A, Hirozane T, Kawai A, Uno Y, Moriyama H, Sawa M, Nagakawa Y, Tsuchida A, Matsumoto M, Nakamura M, Nakayama R, Masuda M. Sekita T, et al. Among authors: sawa m. Cancers (Basel). 2020 May 16;12(5):1258. doi: 10.3390/cancers12051258. Cancers (Basel). 2020. PMID: 32429395 Free PMC article.
Pharmacological blockage of transforming growth factor-β signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846.
Sugano T, Masuda M, Takeshita F, Motoi N, Hirozane T, Goto N, Kashimoto S, Uno Y, Moriyama H, Sawa M, Nagakawa Y, Tsuchida A, Seike M, Gemma A, Yamada T. Sugano T, et al. Among authors: sawa m. Br J Cancer. 2021 Jan;124(1):228-236. doi: 10.1038/s41416-020-01162-3. Epub 2020 Nov 27. Br J Cancer. 2021. PMID: 33244122 Free PMC article.
Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.
Uitdehaag JC, de Roos JA, Prinsen MB, Willemsen-Seegers N, de Vetter JR, Dylus J, van Doornmalen AM, Kooijman J, Sawa M, van Gerwen SJ, de Man J, Buijsman RC, Zaman GJ. Uitdehaag JC, et al. Among authors: sawa m. Mol Cancer Ther. 2016 Dec;15(12):3097-3109. doi: 10.1158/1535-7163.MCT-16-0403. Epub 2016 Sep 1. Mol Cancer Ther. 2016. PMID: 27587489
613 results